This is a significant breakthrough, as traditional BPC-157 was primarily administered via injection in early research settings, making oral delivery a long-standing challenge
Have kidney or liver disease
(3) A Bjartell, R Ekman, S Bergquist, and E Widerlv (1989) Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man Psychoneuroendocrinology, 1989, Volume 14 (Issue 5), Pages 347-55
MOTS-C improves the second at the cellular level
Mitchell et al.[6] measured the level of GSH depletion in the liver (of mice), and the amount of covalent binding of radiolabeled APAP metabolites (later identified as NAPQI) in the liver after a wide range of doses of APAP
Marketing claims around 'reduced L-glutathione' or 'pharmaceutical-grade GSH' are irrelevant if the formulation doesn't address gut degradation